RYVU Therapeutics S.A. — M&A Activity 2021

Dec 14, 2021

The Management Board of Ryvu Therapeutics S.A. with its registeredoffice in Kraków (_quot;Company_quot;, _quot;Ryvu_quot;) hereby informs, in connection withthe current stock report RB no 7/2020 dated 16th of April 2020, that theCompany has received yesterday a notice from Galapagos NV with itsregistered office in Mechelen, Belgium ("Galapagos"), indicating thatGalapagos has chosen to exercise its option under the Option, Licenseand Research Collaboration Agreement ("Agreement"), to obtain anexclusive license to continue the research, development andcommercialization of the program with therapeutic potential ininflammatory diseases based on compounds discovered and developed byRyvu. Upon execution of the option, Ryvu is eligible to receive anoption exercise fee in the amount of EUR 1,250,000 (PLN 5,775,500converted at the rate of NBP from 13th of December 2021, EUR 1 = PLN4.6204) and is eligible to receive research and development milestonepayments, as well as royalties on future sales.

The joint research collaboration under the Agreement is focused on thediscovery and development of novel small molecule drugs in the area ofinflammation, with Ryvu responsible for the early drug discovery. Thecollaboration is based on a novel drug target identified initially byRyvu and is driven by the joint effort of scientific teams from bothcompanies, supported by the Ryvu's resources and expertise inhigh-throughput screening, medicinal chemistry and biology.